argenx SE (Euronext and Nasdaq: ARGX) has agreed to acquire Forte Biosciences, Inc. (Nasdaq: FBRX) for $77 per share in cash, valuing the clinical-stage biotechnology company at approximately $2.2 billion. The transaction gives argenx control of FB102, an investigational anti-CD122 monoclonal antibody that has generated early randomized clinical signals in vitiligo and celiac disease but has not yet progressed through a confirmatory late-stage development programme.
The companies plan to complete the acquisition through a cash tender offer followed by a merger. The offer requires the tender of at least a majority of Forte Biosciences’ outstanding shares and remains subject to customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Both boards have approved the transaction, which is expected to close during the third quarter of 2026 and is not subject to a financing condition.
The deal is strategically understandable but financially substantial. argenx is not buying an established revenue stream, an approved medicine or a programme approaching regulatory submission. It is committing $2.2 billion to a single clinical candidate whose value depends on whether encouraging findings from small Phase 1b studies can be reproduced in larger trials, translated into clinically meaningful outcomes and developed across several autoimmune diseases without losing the biological selectivity that made FB102 attractive in the first place.
Why is argenx moving from a strategic investment to complete ownership of Forte Biosciences?
argenx had already established a strategic relationship with Forte Biosciences before deciding to acquire the company. The buyer said the subsequent vitiligo results and earlier celiac disease findings provided the clinical validation needed to move from minority exposure to full ownership. The acquisition therefore appears to be a staged business-development decision rather than a sudden attempt to buy an untested mechanism.
That distinction matters because biotechnology acquisitions often force buyers to choose between paying early, before risk has been reduced, or waiting until stronger evidence attracts competing bidders and pushes valuations higher. argenx waited for randomized patient data in two diseases, but it is still acting before Phase 2 confirmation in celiac disease and before meaningful efficacy data have been reported in alopecia areata.
The $77 offer represents an approximately 86% premium to Forte Biosciences’ volume-weighted average share price since the company announced its vitiligo data on July 9, 2026. Measured against Forte Biosciences’ July 24 closing price of $54.78, immediately before the Sunday transaction announcement, the offer represents a premium of about 41%.
The difference between those premium calculations tells an important part of the story. Forte Biosciences shares had already risen sharply after the vitiligo readout, climbing from $20.58 on July 8 to $54.78 on July 24. The acquisition therefore rewards shareholders above an already elevated clinical-data valuation rather than rescuing a company whose pipeline had been ignored by the market.
How persuasive are the Phase 1b FB102 results reported in non-segmental vitiligo?
The recently reported vitiligo study provides the most immediate explanation for the timing of the acquisition. Forte Biosciences enrolled 43 participants in a randomized, double-blind, placebo-controlled Phase 1b study, assigning 32 to FB102 and 11 to placebo. The primary endpoint assessed the mean percentage improvement from baseline in the facial Vitiligo Area Scoring Index, or FVASI, using central review.
In the protocol-defined efficacy-evaluable population, FB102-treated participants recorded a 29.6% mean FVASI improvement at week 24, compared with 7.9% for placebo. Forte Biosciences reported a placebo-adjusted benefit of 21.7 percentage points and a p-value of 0.020. The company also reported that improvement became statistically significant by day 64 and continued after the 12-week treatment period had ended.
The intention-to-treat analysis produced a wider separation because the placebo group included one participant who was excluded from the protocol-defined efficacy population because facial hair affected assessment. Including that participant, placebo recipients experienced a mean 16.2% deterioration, while the FB102 group maintained its 29.6% improvement. This generated a placebo-adjusted difference of 45.8 percentage points and a p-value of 0.005.
The results become more visually compelling in participants with greater baseline facial involvement. Among those with a baseline FVASI of at least 0.75, FB102 produced a 43.2% mean improvement compared with 0.5% for placebo. However, that analysis involved only 17 FB102 recipients and four placebo recipients, making it a potentially useful hypothesis for dose and population selection rather than a definitive description of the treatment effect expected in broader clinical practice.
The company reported that all adverse events were mild or moderate and that FB102 compared favourably with placebo during the disclosed follow-up period. That is encouraging for continued development, but the study was too small and too short to establish a complete safety profile for an antibody designed to alter T-cell and natural killer cell activity. Larger trials will need to characterize infections, immune effects, laboratory abnormalities, treatment discontinuations and any consequences of repeated or prolonged dosing.
The commercial opportunity in vitiligo is no longer defined by a complete absence of pharmacologic therapy. The United States Food and Drug Administration has approved topical ruxolitinib cream for non-segmental vitiligo in adults and adolescents aged 12 years and older, with treatment limited by the labelled body-surface-area parameters. A systemic antibody could potentially address a different treatment need, particularly in patients with more extensive disease, but FB102 would need stronger efficacy, safety and durability evidence before such positioning could be established.
Why will the Phase 2 celiac disease readout be the defining near-term test for FB102?
The celiac disease programme arguably carries greater near-term strategic weight because it has progressed into Phase 2 and targets a condition still managed principally through lifelong avoidance of gluten. Current guidance from the National Institute of Diabetes and Digestive and Kidney Diseases and the United States Food and Drug Administration continues to describe adherence to a gluten-free diet as the central treatment approach.
Forte Biosciences’ Phase 1b celiac study enrolled 32 participants, with 24 receiving FB102 and eight receiving placebo. Participants received four 10 mg/kg doses and underwent a 16-day oral gluten challenge. The study evaluated safety, gastrointestinal symptoms, inflammatory changes and measures of intestinal morphology rather than testing routine long-term use under normal dietary conditions.
The company reported a statistically significant difference on a composite histological endpoint combining the villous-height-to-crypt-depth ratio and intraepithelial lymphocyte density. Placebo recipients recorded a mean change of negative 1.849 on this composite measure, compared with 0.079 in the FB102 group, producing a p-value of 0.0099. CD3-positive intraepithelial lymphocyte density increased by 13.3 from baseline with placebo but declined by 1.5 with FB102, with a reported p-value of 0.0035.
Forte Biosciences also reported fewer gluten challenge-related gastrointestinal events among FB102 recipients, with four events per participant compared with 6.9 for placebo. No participants dropped out, and no Grade 3 or higher serious adverse events were reported in the FB102 arm during the disclosed study period. These findings support further evaluation, but the small placebo group and short, controlled gluten challenge mean that the results should not be treated as proof that FB102 can protect patients from repeated accidental exposure or permit dietary liberalisation.
Additional analyses presented at the Tampere Celiac Disease Symposium showed effects on T-cell proliferation and inflammatory biomarkers. Forte Biosciences reported reductions in TCR gamma delta cell density, less expansion of Ki67-positive intraepithelial cells and a 95% decline in natural killer cells following FB102 dosing, without a statistically significant difference in regulatory T cells between the treatment groups. These biomarker findings strengthen the proposed biological rationale, although they do not independently establish durable clinical benefit.
The ongoing Phase 2 study is designed as a randomized, double-blind and placebo-controlled trial in approximately 100 adults with well-controlled celiac disease who follow a strict gluten-free diet and then undergo an oral gluten challenge. Forte Biosciences and argenx have said that Phase 2 data are expected during the second half of 2026. The ClinicalTrials.gov record, however, currently lists estimated primary and study completion in February 2027, making the timing, patient cutoff and scope of the expected 2026 disclosure important details for investors and clinicians to examine.
What makes anti-CD122 biology different from argenx’s existing autoimmune disease platforms?
CD122 is a receptor subunit used in signalling by interleukin-2 and interleukin-15, cytokines involved in the regulation and activation of natural killer cells and multiple T-cell populations. Forte Biosciences designed FB102 to inhibit pathogenic immune activity associated with these pathways while attempting to preserve regulatory T-cell function.
The proposed differentiation depends on balance rather than maximum immune suppression. Forte Biosciences has argued that FB102 may modulate both IL-2-dependent and IL-15-dependent pathogenic activity without producing the same regulatory T-cell effects that could accompany excessive CD122 blockade. The reported biomarker data are consistent with that hypothesis, but confirmation will require larger studies that directly characterize dose response, immune-cell recovery, infection risk and longer-term pharmacodynamic effects.
For argenx, this mechanism expands the company beyond the biology that underpins its current commercial success. Its principal franchise, VYVGART, reduces circulating immunoglobulin G antibodies by blocking the neonatal Fc receptor. Other argenx programmes target complement, IgA, muscle-specific kinase and additional immunological pathways. FB102 adds a mechanism directed more directly toward pathogenic T-cell and natural killer cell activity, potentially opening disease areas that may not be optimally addressed through autoantibody reduction alone.
Management describes FB102 as a potential pipeline-in-a-product because the same mechanism could be studied in vitiligo, celiac disease, alopecia areata and other immune-mediated disorders. The phrase captures the strategic opportunity but also the principal development risk. Activity in two early trials does not guarantee that the antibody will work across diseases with different tissues, inflammatory drivers, endpoints and treatment expectations.
Alopecia areata provides the next opportunity to test the breadth of the platform. Forte Biosciences has been conducting a Phase 1b programme in that condition, but no efficacy dataset comparable with the vitiligo or celiac disease disclosures has yet established activity. argenx will therefore inherit both a development opportunity and the responsibility to decide which indications merit substantial investment.
Can argenx finance the $2.2 billion acquisition without weakening its existing pipeline?
argenx enters the transaction from an unusually strong financial position for a biotechnology company. The company reported $1.5 billion in second-quarter 2026 global product net sales and $2.8 billion for the first half, driven overwhelmingly by VYVGART. It generated approximately $500 million in quarterly profit and $700 million in operating cash flow during the first six months of the year.
Cash, cash equivalents and current financial assets totalled $5.2 billion at June 30, 2026. The $2.2 billion acquisition price therefore represents approximately 42% of that liquidity before transaction expenses and subsequent operating requirements. argenx can fund the purchase without external financing, but the commitment is large enough to make clinical prioritisation and development spending consequential.
The acquisition should not threaten the immediate commercial operation of VYVGART, which is generating substantial cash and continues to expand across autoimmune indications. The more relevant question is opportunity cost. Capital allocated to FB102 cannot simultaneously be used for additional acquisitions, internal programmes, manufacturing investments or shareholder returns.
The market had not yet had an opportunity to price the acquisition when it was announced on Sunday, July 26. argenx American depositary shares closed at $912.71 on July 24, while Forte Biosciences closed at $54.78. argenx shares had already risen after the company’s July 23 quarterly results, placing the stock close to the upper end of its recent trading range before the acquisition announcement.
Investors are likely to distinguish between the strategic quality of the asset and the price paid for it. Positive Phase 2 celiac data could make the acquisition appear well timed, particularly if argenx can accelerate development across multiple diseases. An ambiguous or negative readout would expose how much of the transaction value rests on extrapolation from small studies.
What must happen for FB102 to justify argenx’s acquisition price and pipeline expectations?
The first requirement is a credible Phase 2 celiac disease dataset with clearly defined statistical analysis, balanced baseline characteristics and consistent results across histology, symptoms and inflammatory biomarkers. The readout will also need enough safety detail to show whether CD122 modulation can be repeated at clinically useful exposure levels.
The second requirement is confirmation of the vitiligo signal in a larger study. Future development will need to establish the magnitude and durability of repigmentation, performance across facial and total-body disease, the value of continued treatment and the patient population most likely to benefit. The small baseline-severity subgroup may help guide trial design, but it should not be treated as a confirmed responder population.
The third requirement is disciplined indication selection. A broad mechanism can create many possible development programmes, but each additional disease increases clinical spending and operational complexity. argenx will need to decide whether FB102 should initially be concentrated in celiac disease and vitiligo or advanced simultaneously into alopecia areata and other conditions.
Manufacturing and regulatory strategy will become more important as the programme matures. A monoclonal antibody intended for chronic autoimmune disease requires scalable production, consistent product quality and a dosing schedule that is acceptable to patients and payers. Fast Track designation in celiac disease, as reported by Forte Biosciences, may facilitate interactions with the United States Food and Drug Administration, but it does not reduce the need for persuasive efficacy and safety evidence or guarantee approval.
The acquisition gives argenx ownership of a potentially differentiated mechanism at a moment when its commercial franchise is producing enough cash to support substantial external investment. It also raises the standard FB102 must meet. Following a $2.2 billion transaction, modest biological activity will not be sufficient. The programme will need to demonstrate reproducible clinical benefit, manageable immune effects and credible utility across at least one major indication before the strategic promise of an anti-CD122 pipeline can begin to resemble the value already paid for it.
